Drug Profile
Cannabidiol oral - Sapient Therapeutics
Alternative Names: SAP-021; SAP-021-T1; SAP-021-T2; Solid dose CBD - Sapient TherapeuticsLatest Information Update: 21 Dec 2023
Price :
$50
*
At a glance
- Originator Sapient Therapeutics
- Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antibacterials; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Cannabinoids; Cardiovascular therapies; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Obesity therapies; Resorcinols; Skin disorder therapies; Small molecules
- Mechanism of Action 5-HT1 serotonin receptor modulators; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Transient receptor potential channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Neurological disorders
- Clinical Phase Unknown Psychiatric disorders
Most Recent Events
- 20 Dec 2023 Adverse event and Pharmacokinetics data from a phase I trial in volunteers released by Sapient Therapeutics
- 20 Dec 2023 Sapient Therapeutics completes a phase I trial in Neurological disorders (In volunteers) in Australia (PO)
- 20 Dec 2023 Sapient Therapeutics plans a clinical trial in Neurological disorders (PO)